Companies / ABBV vs VRTX
ABBV vs VRTX: AbbVie and Vertex Pharmaceuticals
AbbVie (ABBV) reported $61.2B in revenue against a 6.9% net margin, while Vertex Pharmaceuticals (VRTX) reported $12.0B at a 32.9% net margin, most recently.
| Metric | ABBV | VRTX |
|---|---|---|
| Revenue | $61.2B | $12.0B |
| Net Income | $4.2B | $4.0B |
| Gross Margin | 70.2% | 86.2% |
| Operating Margin | 24.6% | 34.8% |
| EPS (Diluted) | $2.36 | $15.32 |
| Free Cash Flow | $17.8B | $3.2B |
| Total Debt | $67.0B | — |
| P/E Ratio | 96.8× | 29.6× |
| P/B Ratio | n/m | 6.2× |
| Stock Price | $288.14 | $542.69 |
Free: last 5 years
| Fiscal year | FY2011 🔒 | FY2012 🔒 | FY2013 🔒 | FY2014 🔒 | FY2015 🔒 | FY2016 🔒 | FY2017 🔒 | FY2018 🔒 | FY2019 🔒 | FY2020 🔒 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABBV Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $56.2B | $58.1B | $54.3B | $56.3B | $61.2B |
| VRTX Revenue | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | ••••• | $7.6B | $8.9B | $9.9B | $11.0B | $12.0B |